Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical Data Multiple myeloma (MM), the second ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory ...

Among patients with relapsed/refractory multiple myeloma, fixed-dose subcutaneous treatment with Sarclisa (isatuximab ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, an ...

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose ...

Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing ...

Panelists discuss how guideline-recommended treatment regimens for patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma should be evaluated and selected based on ...

Delayed diagnosis causes a significant disadvantage for Hungarian patients adding cost and complexity to the already stretched healthcare system.

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...